The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effects of colestipol-niacin therapy on human femoral atherosclerosis.
Open accessAbstract
The 2-year therapy effect on femoral atherosclerosis was evaluated in the Cholesterol Lowering Atherosclerosis Study (CLAS), a randomized, placebo-plus-diet-controlled angiographic trial of colestipol-niacin therapy plus diet in men with previous coronary bypass surgery. Different diet compositions were prescribed to enhance the differential in blood cholesterol responses between the two groups. The annual rate of change in computer-estimated atherosclerosis (CEA), a measure of lumen abnormality, was evaluated between treatment groups. A significant per-segment therapy effect was found in segments with moderately severe atherosclerosis (p less than 0.04) and in proximal segments (p less than 0.02). When segmental CEA measures were combined into a per-patient score using an adaptation of the National Heart, Lung, and Blood Institute scoring procedure, a significant therapy effect was observed (p less than 0.02). Total variance of the annual change rate in CEA was as predicted from pilot studies, but measurement variation was larger. The therapy effect observed in femoral arteries, although significant, was less marked than the strong and consistent benefit previously reported for both native coronary arteries and aortocoronary bypass grafts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Blankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P. (1990) · Circulation · doi:10.1161/01.cir.81.2.470 · Cited by 278
Self-citation
Cited by
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2006.12.037 · Cited by 8,191
Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)
Norgren, L., Hiatt, W. R., Dormandy, J. A., Nehler, M. R., Harris, K. A., & Fowkes, F. G. R. (2007) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2006.09.024 · Cited by 2,840
The Role of Carotid Arterial Intima-Media Thickness in Predicting Clinical Coronary Events
Hodis, H. N., Mack, W. J., LaBree, L., Selzer, R. H., Liu, C.-R., Liu, C.-H., & Azen, S. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-4-199802150-00002 · Cited by 1,217
Self-citationMedical treatment of peripheral arterial disease and claudication
Hiatt, W. R. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442108 · Cited by 1,121
Watts, G. F., Lewis, B., Lewis, E. S., Coltart, D. J., Smith, L. D. R., Swan, A. V., Brunt, J. N. H., & Mann, J. I. (1992) · The Lancet · doi:10.1016/0140-6736(92)90863-x · Cited by 843
Sorensen, K. E., Celermajer, D. S., Georgakopoulos, D., Hatcher, G., Betteridge, D. J., & Deanfield, J. E. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116983 · Cited by 578
Mohler, E. R., Hiatt, W. R., & Creager, M. A. (2003) · Circulation · doi:10.1161/01.cir.0000090686.57897.f5 · Cited by 479
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Pedersen, T. R., Kjekshus, J., Pyörälä, K., Olsson, A. G., Cook, T. J., Musliner, T. A., Tobert, J. A., & Haghfelt, T. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00904-1 · Cited by 466
Peripheral arterial disease - epidemiological aspects
Criqui, M. H. (2001) · Vascular Medicine · doi:10.1177/1358836x0100600i102 · Cited by 351
Bruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273
G protein-coupled receptors for energy metabolites as new therapeutic targets
Blad, C. C., Tang, C., & Offermanns, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3777 · Cited by 273
Efficacy and safety of an extended-release niacin (Niaspan): a long-term study
Capuzzi, D. M., Guyton, J. R., Morgan, J. M., Goldberg, A. C., Kreisberg, R. A., Brusco, O. A., & Brody, J. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00731-0 · Cited by 254
Walldius, G., Erikson, U., Olsson, A. G., Bergstrand, L., Hådell, K., Johansson, J., Kaijser, L., Lassvik, C., Mölgaard, J., Nilsson, S., et al. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90579-7 · Cited by 248
Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., & Hayashi, J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01783-1 · Cited by 226
Niacin dosing: Relationship to benefits and adverse effects
Capuzzi, D. M., Morgan, J. M., Brusco, O. A., & Intenzo, C. M. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0096-y · Cited by 88
Metadata
- Authors
- Blankenhorn, D. H., Azen, S. P., Crawford, D. W., Nessim, S. A., Sanmarco, M. E., Selzer, R. H., Shircore, A. M., & Wickham, E. C.
- Venue
- Circulation
- Published
- 1991-02
- Volume
- 83
- Issue
- 2
- Pages
- 438-447
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2155655406
- Cited by
- 173
- References
- 2
- FWCI
- 12.87
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.